These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 1695077)

  • 1. Immunohistochemical staining of human breast cancer with a new tumour marker MCA: relation to axillary lymph node involvement, metastasis, and survival.
    Eskelinen M; Lipponen P; Collan Y
    Anticancer Res; 1990; 10(3):591-6. PubMed ID: 1695077
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TAG 12 expression as a prognostic factor in female breast cancer.
    Eskelinen M; Lipponen P; Syrjänen K
    Anticancer Res; 1991; 11(5):1683-6. PubMed ID: 1768037
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MCA performance in preoperative breast cancer patients.
    Donadeo A; Micelli G; Quaranta M; Atlante A; Schittulli F
    Anticancer Res; 1995; 15(2):527-9. PubMed ID: 7763034
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An evaluation of the usefulness of primary tumour expression of MCA and CA15-3 as prognostic indicators in breast carcinoma.
    Byrne J; Horgan PG; England S; Callaghan J; Given HF
    Eur J Surg Oncol; 1992 Jun; 18(3):230-4. PubMed ID: 1607033
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A new tumor marker MCA in breast cancer diagnosis.
    Eskelinen M; Tikanoja S; Collan Y
    Anticancer Res; 1988; 8(4):665-8. PubMed ID: 3178156
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression and possible prognostic role of MAGE-A4, NY-ESO-1, and HER-2 antigens in women with relapsing invasive ductal breast cancer: retrospective immunohistochemical study.
    Bandić D; Juretić A; Sarcević B; Separović V; Kujundzić-Tiljak M; Hudolin T; Spagnoli GC; Cović D; Samija M
    Croat Med J; 2006 Feb; 47(1):32-41. PubMed ID: 16489695
    [TBL] [Abstract][Full Text] [Related]  

  • 7. LEA-135 expression: its association with a lower risk of recurrence and increased overall survival of patients with lymph node-positive primary invasive breast cancer.
    Saha B; Zhang N; Naritoku WY; Tsao-Wei DD; Groshen SL; Carlsson G; Larsson L; Gustavsson B; Chaiwun B; Taylor CR; Imam SA
    Anticancer Res; 2004; 24(4):2391-400. PubMed ID: 15330189
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of tumour markers CA50, CEA and TPA in female breast carcinoma as related to histopathological findings and survival.
    Eskelinen M; Lipponen P; Syrjänen K
    Anticancer Res; 1992; 12(1):91-5. PubMed ID: 1567186
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Percent positive axillary lymph node metastasis predicts survival in patients with non-metastatic breast cancer.
    Lale Atahan I; Yildiz F; Ozyigit G; Sari S; Gurkaynak M; Selek U; Hayran M
    Acta Oncol; 2008; 47(2):232-8. PubMed ID: 17924207
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cysteine proteinase inhibitor cystatin A in breast cancer.
    Kuopio T; Kankaanranta A; Jalava P; Kronqvist P; Kotkansalo T; Weber E; Collan Y
    Cancer Res; 1998 Feb; 58(3):432-6. PubMed ID: 9458085
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunohistochemical demonstration of c-erb B-2 oncoprotein expression in female breast cancer and its prognostic significance.
    Tervahauta A; Eskelinen M; Syrjänen S; Lipponen P; Pajarinen P; Syrjänen K
    Anticancer Res; 1991; 11(5):1677-81. PubMed ID: 1685075
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of E-cadherin (E-CD) as related to other prognostic factors and survival in breast cancer.
    Lipponen P; Saarelainen E; Ji H; Aaltomaa S; Syrjänen K
    J Pathol; 1994 Oct; 174(2):101-9. PubMed ID: 7965405
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early distant relapse in "node-negative" breast cancer patients is not predicted by occult axillary lymph node metastases, but by the features of the primary tumour.
    Colpaert C; Vermeulen P; Jeuris W; van Beest P; Goovaerts G; Weyler J; Van Dam P; Dirix L; Van Marck E
    J Pathol; 2001 Apr; 193(4):442-9. PubMed ID: 11276002
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The significance of nuclear morphometric variables as prognostic predictors in breast cancer.
    Aaltomaa S; Lipponen P; Eskelinen M; Kosma VM; Marin S; Alhava E; Syrjänen K
    Anticancer Res; 1991; 11(4):1663-9. PubMed ID: 1746922
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biological significance of occult micrometastases in histologically negative axillary lymph nodes in breast cancer patients using the recent American Joint Committee on Cancer breast cancer staging system.
    Kahn HJ; Hanna WM; Chapman JA; Trudeau ME; Lickley HL; Mobbs BG; Murray D; Pritchard KI; Sawka CA; McCready DR; Marks A
    Breast J; 2006; 12(4):294-301. PubMed ID: 16848838
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation of tumor size and axillary lymph node involvement with prognosis in patients with T1 breast carcinoma.
    Abner AL; Collins L; Peiro G; Recht A; Come S; Shulman LN; Silver B; Nixon A; Harris JR; Schnitt SJ; Connolly JL
    Cancer; 1998 Dec; 83(12):2502-8. PubMed ID: 9874455
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of epidermal growth factor receptor (EGFR) in breast cancer as related to clinical, prognostic and cytometric factors.
    Pirinen R; Lipponen P; Syrjänen K
    Anticancer Res; 1995; 15(6B):2835-40. PubMed ID: 8669874
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [MCA and CA 15-3 in the follow-up of patients with breast cancer].
    Hammer J; Track C; Hohenwallner W; Seewald DH; Zoidl JP; Wimmer E
    Strahlenther Onkol; 1992 Feb; 168(2):102-6. PubMed ID: 1542844
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic significance of the metastasis-associated protein osteopontin in human breast cancer.
    Rudland PS; Platt-Higgins A; El-Tanani M; De Silva Rudland S; Barraclough R; Winstanley JH; Howitt R; West CR
    Cancer Res; 2002 Jun; 62(12):3417-27. PubMed ID: 12067984
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sentinel lymph node as a new marker for therapeutic planning in breast cancer patients.
    Gipponi M; Bassetti C; Canavese G; Catturich A; Di Somma C; Vecchio C; Nicolò G; Schenone F; Tomei D; Cafiero F
    J Surg Oncol; 2004 Mar; 85(3):102-11. PubMed ID: 14991881
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.